TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sera Prognostics ( (SERA) ) has issued an announcement.
On November 24, 2025, Sera Prognostics announced that the findings of its PRIME study, one of the largest studies on preterm birth, were accepted for publication in a peer-reviewed journal. This development highlights the company’s commitment to advancing maternal and neonatal health through innovative research, potentially enhancing its industry positioning and providing significant insights for stakeholders.
The most recent analyst rating on (SERA) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Sera Prognostics stock, see the SERA Stock Forecast page.
Spark’s Take on SERA Stock
According to Spark, TipRanks’ AI Analyst, SERA is a Neutral.
Sera Prognostics’ overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and significant losses. Technical analysis provides a slightly better outlook but remains weak. Valuation metrics are unfavorable due to negative earnings and lack of dividends. Strategic initiatives mentioned in the earnings call offer some hope but are overshadowed by financial challenges.
To see Spark’s full report on SERA stock, click here.
More about Sera Prognostics
Sera Prognostics is a health diagnostics company dedicated to improving maternal and neonatal health through precision pregnancy care. The company offers the PreTRM® Test, a validated blood-based biomarker test for early risk prediction of spontaneous preterm birth, and is headquartered in Salt Lake City, Utah.
Average Trading Volume: 60,419
Technical Sentiment Signal: Sell
Current Market Cap: $124.7M
See more insights into SERA stock on TipRanks’ Stock Analysis page.